MIR3613: MIR3613 is a gene that has been studied in relation to breast cancer (BC) and has been found to be deleted in the BC genome. This deletion has been shown to be correlated with molecular subtypes and an unfavorable prognosis in estrogen receptor-positive (ER+) BC patients [PMC8131824]. The correlation between MIR3613 copy number and PAM50 subtypes was analyzed using a chi-square test, and the analysis was adjusted by Bonferroni correction [PMC7836180]. The deletion of MIR3613 was found to be associated with breast cancer subtypes and the survival of ER+ BC patients [PMC7836180]. The expression of stemness genes, such as SOX2, NANOG, and LIN28B, was significantly higher in the MIR3613 deletion group compared to the non-deletion group [PMC7836180]. Copy number variations (CNVs) of MIR3613 were analyzed across various cancer types using The Cancer Genome Atlas (TCGA) dataset [PMC7836180]. The expression of cell cycle-related genes was also higher in breast cancer patients with high expression of three target genes or MIR3613 deletion compared to their counterparts [PMC7836180]. A lower frequency of MIR3613 deletion was observed in PAM50 subtypes with a comparatively favorable prognosis, such as luminal A subtype, while ER+ BC patients with MIR3613 deletion had a worse prognosis compared to the non-deletion group [PMC7836180]. The locus of MIR3613 is located near tumor suppressor genes RB1 and BRCA2 on chromosome 13, and copy number alterations were frequently observed in breast cancer [PMC7836180]. NEAT1 expression was decreased in the MIR3613 deletion group, while high NEAT1 expression tended to be associated with prolonged survival in breast cancer patients [PMC7836180]. The deletion of MIR3613 was found to be common in breast cancer patients [PMC7836180]. Although no significant correlation was observed between MIR3613 copy number and survival in the whole cohort or ER-negative subset of breast cancer patients, the proportion of MIR3613 deletions in the TCGA breast cancer cohort was studied [PMC7836180]. The MIR3613 locus was frequently deleted in breast cancer tissues based on whole exome sequencing data from TCGA [PMC7836180]. In conclusion, the deletion of MIR3613 is associated with an unfavorable prognosis in ER+ BC patients and is frequently observed in breast cancer tissues [PMC8131824] [PMC7836180] [PMC8261273] [PMC8216629].